Table 2.

Recommendations about IgRT application based on clinical guidelines.

Guideline	HSCT/non-HSCT setting	Suitable candidates for IgRT	References
French expert consensus	Non-HSCT	All PID patients	[17]
UK expert consensus	Non-HSCT	Patients who suffered from recurrent or severe infection with encapsulated bacteria and had a serum IgG <500 mg/dl	[18]
NCCN	Non-HSCT	Patients who had recurrent serious infection with a serum IgG <400 mg/dl	[23]
NCCN	Non-HSCT	Patients who had recurrent sinopulmonary infection with a serum IgG <500 mg/dl	[24]
ASBMT/CBMT	HSCT	CBT recipients, children who undergo transplantation for inherited or acquired disorders associated with B-cell deficiency, and chronic GVHD patients with recurrent sinopulmonary infections	[46]
ASBMT	HSCT	High-risk recipients who undergo unrelated HSCT with IgG <400 mg/dL	[47]
NCCN	HSCT	Allo-recipients who had recurrent infection with a seum IgG <400 mg/dl	[48]
European expert consensus	HSCT	All allo-recipients (particularly patients with low IgG level (<400 mg/dl) or with GVHD on immunosuppressive treatment)	[50]
JSHCT	HSCT	Allo-recipients with pre-transplant IgG <400 mg/dl or with delayed immunoglobulin recovery after HSCT	[51]
AAAAI	HSCT	Recipients with IgG <400 mg/dL who had bacteremia or recurrent sinopulmonary infection	[52]

NCCN National Comprehensive Cancer Network, ASBMT American Society for Blood and Marrow Transplantation, CBMT Canadian Blood and Marrow Transplant, JSHCT Japanese Society for Hematopoietic Cell Transplantation, AAAAI American Academy of Allergy, Asthma and Immunology, HSCT hematopoietic stem-cell transplantation, IgRT immunoglobulin replacement therapy, PID primary immunodeficiency, CBT cord blood transplant, GVHD graft-versus-host disease.